Scolaris Content Display Scolaris Content Display

Hormone replacement therapy after surgery for epithelial ovarian cancer

Esta versión no es la más reciente

ver la versión actual 28 enero 2020

Appendices

Appendix 1. MEDLINE Ovid search strategy

1. exp Ovarian Neoplasms/
2. (ovar* adj5 (cancer* or neoplas* or tumor* or tumour* or carcinoma* or adenocarcinoma* or malignan*)).mp.
3. 1 or 2
4. exp Hysterectomy/
5. hysterectom*.mp.
6. Salpingectomy/
7. (salpingectomy or salpingo‐oophorectomy or salpingooophorectomy).mp.
8. 4 or 5 or 6 or 7
9. exp Hormone Replacement Therapy/
10. (hormone replacement or HRT).mp.
11. exp Estrogens/
12. exp Estrogen Antagonists/
13. (estrogen* or oestrogen*).mp.
14. exp Progestins/
15. exp Progesterone/
16. progest*.mp.
17. exp Testosterone/
18. testosterone.mp.
19. tibolone.mp.
20. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19
21. 3 and 8 and 20

Key:
[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier]

Appendix 2. Outline 'Summary of findings' table

Title: Hormone replacement therapy (HRT) for women with epithelial ovarian cancer after hysterectomy and bilateral salpingo‐oophorectomy

Patient or population: women with stage IA2‐IB1 cervical cancer

Settings: specialist hospital/outpatient

Intervention: HRT; oestrogen‐alone, and oestrogen combined with progestin, oestrogen agonist/antagonist, testosterone or tibolone in any dose and route of administration

Comparison: placebo or no HRT

Outcomes

Illustrative comparative risks*

Relative effect (95% CI)

No of participants

(studies)

Quality of evidence

(GRADE)

Comment

Assumed risk

Corresponding risk

Overall survival

[Delete as
appropriate for each outcome]

⊕⊝⊝⊝
very low

⊕⊕⊝⊝
low

⊕⊕⊕⊝
moderate

⊕⊕⊕⊕
high

Possibly discuss the subgroup findings/effects in this column

Quality of life assessment

Progression‐free survival

Incidence of breast cancer

Incidence of thromboembolic events

Incidence of MI

Incidence of stroke

Incidence of gallstones

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; HR: hazard ratio; MD: mean difference; RR: risk ratio; OR: odds ratio

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.